Aroa Biosurgery Launches New Product, Myriad Morcells™ - Offering Highly Conformable Tissue Regeneration in Wound Beds

Aroa Biosurgery Launches New Product, Myriad Morcells™ - Offering Highly Conformable Tissue Regeneration in Wound Beds - Following Recent FDA Clearance
HIGHLIGHTS
Soft tissue regeneration company Aroa Biosurgery Limited has this week launched a new product named Myriad Morcells™, a morcellized (powder) format of Myriad Matrix™ that easily conforms to optimize contact with irregular wound beds.
It received U.S. FDA 510(k) clearance received for the product on 6 April 2021.
The morcellized format increases AROA ECM™ surface area to maximize delivery of important ECM proteins.
This clearance further builds on applications for the Myriad™ portfolio, following recent studies showing positive clinical outcomes for Myriad Matrix™’s use in surgical treatment of hidradenitis suppurativa, complex wounds and exposed vital structures.

Related Keywords

United States ,Australia ,New Zealand ,Australian ,Brian Ward ,Mediaaustralia Matthew Wright ,Simon Hinsley ,Aroa Biosurgery ,Aroa Biosurgery Limited ,Australian Securities Exchange ,Clinical Development ,Myriad Morcells ,Myriad Matrix ,Surgeon Advisory ,Vice President ,Barnaby May ,Aroa Founder ,Aroa Biosurgery Board ,ஒன்றுபட்டது மாநிலங்களில் ,ஆஸ்திரேலியா ,புதியது ஜீலாந்து ,ஆஸ்திரேலிய ,பிரையன் வார்டு ,ஆஸ்திரேலிய பத்திரங்கள் பரிமாற்றம் ,மருத்துவ வளர்ச்சி ,துணை ப்ரெஸிடெஂட் ,பர்னபிய இருக்கலாம் ,அரேஞ் நிறுவனர் ,